Health technology assessment of Herpes Zoster (shingles) vaccination

Health Information and Quality Authority
Record ID 32018005546
English
Authors' objectives: Herpes zoster, which is commonly known as shingles, affects approximately one in three people that have had chickenpox. Shingles is typically recognised by a painful blistering rash on the torso. While vaccines against herpes zoster are licensed and marketed in Ireland, these vaccines are not included in the Health Service Executive (HSE) national immunisation schedule. The Department of Health requested that HIQA complete a health technology assessment (HTA) to inform a decision on the addition of shingles vaccination to the adult immunisation schedule. The protocol document outlines the evidence synthesis approach that HIQA’s evaluation team will use to complete this piece of work.
Details
Project Status: Completed
URL for project: https://www.hiqa.ie/reports-and-publications/health-technology-assessment/health-technology-assessment-herpes-zoster
URL for protocol: https://www.hiqa.ie/sites/default/files/2023-12/Herpes-Zoster-project-protocol.pdf
Year Published: 2024
URL for published report: https://www.hiqa.ie/sites/default/files/2024-07/HZ-vaccination-HTA.pdf
Requestor: Department of Health
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Ireland
MeSH Terms
  • Herpes Zoster
  • Mass Vaccination
  • Herpes Zoster Vaccine
  • Adult
  • Vaccination
Keywords
  • Shingles
  • Vaccination
Contact
Organisation Name: Health Information and Quality Authority (HIQA)
Contact Address: Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464
Contact Name: info@hiqa.ie
Contact Email: info@hiqa.ie
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.